Curanex Pharmaceuticals Inc. announced that it has received a notice from the Nasdaq Stock Market indicating that its common stock has closed below the required minimum bid price of $1.00 per share for 30 consecutive business days. This triggers a potential delisting issue under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days, until May 4, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. During this period, Curanex's stock will continue to trade on the Nasdaq Capital Market under the symbol "CURX". If compliance is not regained, the company may be eligible for an additional 180-day extension or could face delisting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-021028), on November 06, 2025, and is solely responsible for the information contained therein.